Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future ...

Torrent has signed definitive agreements to acquire stake in JB Pharma at an equity valuation of Rs256.89bn ($3bn) on a fully ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.